Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

07/15/07	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/15/29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

07/15/07	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/15/29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/15/22	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
22/15/22	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/15/09	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/15/06	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/15/06	Wall Street closes up slightly ahead of jobs report	RE
05/15/05	AbbVie : CEO says new form of Humira could thwart generics	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/15/05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/14/02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/16/08	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/16/08	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/16/08	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/16/08	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/16/08	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/15/06	Wall Street se reprend un peu dans un climat d'attente
06/15/06	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/15/05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/15/05	Début d'année en fanfare pour les fusions dans la pharmacie
05/15/05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.04%	+1.47%	+0.35%	+15.84%	4.85TCr
REVOLUTION MEDICINES, INC.	-1.50%	-0.90%	+411.96%	+472.09%	3.99TCr
IQVIA HOLDINGS INC.	-1.18%	+12.96%	+28.81%	+7.27%	3.87TCr
BEONE MEDICINES AG	-1.23%	-3.03%	+5.69%	+66.52%	3.51TCr
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+44.64%	2.98TCr
MEDPACE HOLDINGS, INC.	-0.42%	-4.04%	+36.40%	+126.06%	1.61TCr
ASCENDIS PHARMA A/S	-0.16%	-3.92%	-	-	1.61TCr
EUROFINS SCIENTIFIC SE	+0.76%	+2.72%	+3.31%	+16.75%	1.36TCr
ICON PUBLIC LIMITED COMPANY	-2.29%	-1.32%	-1.73%	-34.97%	1.26TCr
Average	-0.86%	+0.86%	+62.40%	+89.27%	2.78TCr
Weighted average by Cap.	-0.79%	+1.76%	+80.20%	+108.20%

Employees

Sector